China’s Hinova Pharmaceuticals closed nearly $146 million in a series C round investment to support multicenter clinical trials and the commercialization of their leading drug candidates both domestically and internationally.
Hinova Pharmaceuticals Background
Founded in 2013, Hinova’s R&D focuses on metabolic diseases and cancer. The most promising candidates include an anti-prostate cancer drug in Phase 3 of international multicenter trials, an anti-hyperuricemia and gout drug being developed in Phase 1 clinical trials in China and several other early stage initiatives. Their pipeline can be reviewed here.
What about their management? U.S. or Western experience?
Yes. Their management team has rich Western pharma experience including employment with firms such as Abbott, Bayer, Merck AstraZeneca and more. They also maintain a scientific advisory board consisting of prominent scientists and researchers including Nobel laureates, etc.
Who are the latest investors?
Shenzhen Investment Holdings (state-owned), Hangzhou Tigermed (a contract research organization), Beijing’s Huarong Rongde Asset Management and a private equity fund called Sinopharm-CICC Capital. Previous backers include CCB International, Hongtai Capital Holdings, Sealand Innovation, Infinity Group, Founder H Fund and DNV Capital.